SCHEMBL5308358

SCHEMBL5308358

CN1CCN(c2cc(O)cc3c2OC(C(=O)Nc2ccc(N4CCOCC4)cc2)CC3)CC1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1B P28222 5/20 0.79
▸ KCNH2 Q12809 1/20 0.79
▸ RAD52 P43351 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ MAPT P10636 4/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ NFKB2 Q00653 1/20 0.43
▸ RELA Q04206 1/20 0.43
▸ GAA P10253 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ TP53 P04637 1/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ MTOR P42345 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5308451 0.90 HTR1B (0.78) HTR1BKCNH2RAD52ALDH1A1MAPT
SCHEMBL4247675 0.88 HTR1B (1.00) HTR1BKCNH2RAD52ALDH1A1MAPT
SCHEMBL4247047 0.88 HTR1B (1.00) HTR1BKCNH2RAD52ALDH1A1MAPT
SCHEMBL14525248 0.88 HTR1B (0.74) HTR1BKCNH2RAD52ALDH1A1MAPT
SCHEMBL14370170 0.87 HTR1B (0.73) HTR1BKCNH2RAD52ALDH1A1MAPT
SCHEMBL5354642 0.87 HTR1B (0.73) HTR1BKCNH2RAD52ALDH1A1MAPT
SCHEMBL14263999 0.87 HTR1B (0.73) HTR1BKCNH2RAD52ALDH1A1MAPT
SCHEMBL4250243 0.86 HTR1B (0.71) HTR1BKCNH2RAD52MAPTMEN1
SCHEMBL4246330 0.84 HTR1B (0.93) HTR1BKCNH2ALDH1A1MAPTMEN1
SCHEMBL14525249 0.83 HTR1B (0.68) HTR1BKCNH2RAD52SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 — — US claimed
WO-2007053094-A1 CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS ASTRAZENECA AB (SE) 2007-05-10 — — WO claimed
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 — — US disclosed
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 — — US disclosed
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 — — US disclosed
WO-2007053094-A1 CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS ASTRAZENECA AB (SE) 2007-05-10 — — WO disclosed
WO-2007053094-A1 CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS ASTRAZENECA AB (SE) 2007-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135442-A1 Chroman compounds CYP3A43, CYP2C9, CYP2C8 HTR1B 592/4885KCNH2 1018/4885RAD52 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback